2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4592
    (Glu24)-Glucagon (1-29) (human, rat, porcine) 308356-99-2 98%
    (Glu24)-Glucagon (1-29) (human, rat, porcine) is a fragment of glucagon.
    (Glu24)-Glucagon (1-29) (human, rat, porcine)
  • HY-P4610
    H-Trp-Tyr-OH 19653-76-0 99.43%
    H-Trp-Tyr-OH is an orally active tryptophan-tyrosine dipeptide with blood-brain barrier permeability. H-Trp-Tyr-OH exerts physiological regulatory effects by stimulating enteroendocrine cells to secrete glucagon-like peptide GLP-1. In mouse models of tauopathies, H-Trp-Tyr-OH inhibits tau phosphorylation, reduces the level of neurofibrillary tangles, increases dopamine turnover, upregulates synapsin expression, and elevates cecal short-chain fatty acid levels, thereby improving behavioral deficits and extending lifespan. H-Trp-Tyr-OH can be used in research related to impaired glucose tolerance and tauopathies.
    H-Trp-Tyr-OH
  • HY-P4667
    VLHDDLLEA 204931-32-8 98%
    VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A*0201 molecule. VLHDDLLEA can be recognized by HLA-A*0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD).
    VLHDDLLEA
  • HY-P4672
    (Met(O)27)-Glucagon (1-29) (human, rat, porcine) 75217-63-9 98%
    (Met(O)27)-Glucagon (1-29) (human, rat, porcine) is a modified glucagon. (Met(O)27)-Glucagon (1-29) (human, rat, porcine) has the same maximum glucose-synthesizing activity in rat hepatocytes as native glucagon, but it is less potent, suggesting a crucial role of methionine in the binding of glucagon to its hepatic receptor.
    (Met(O)27)-Glucagon (1-29) (human, rat, porcine)
  • HY-P4681
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) 97773-00-7 98%
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) is a fragment of the ACTH hormone. (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) can be labeled with I125 on Tyr23 to produce a radiolabeled ligand.
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat)
  • HY-P4689
    Prolactin-Releasing Peptide (1-31) (rat) 215510-06-8 98%
    Prolactin-Releasing Peptide (1-31) (rat) is a UHR-1/GRP10 receptor ligand. Prolactin-Releasing Peptide (1-31) (rat) reduces fasting-induced food intake, increases plasma levels of LH, FSH, and testosterone in rats.
    Prolactin-Releasing Peptide (1-31) (rat)
  • HY-P4698
    Tri-valine 28130-13-4 98%
    Tri-valine (NSC 35938) is a polypeptide that can be separated from Creatine kinase (HY-P2799), β-enolase, Triosephosphate isomerase (HY-P2931) and glyceraldehyde 3-phosphate dehydrogenase.
    Tri-valine
  • HY-P4724
    (β-Asp28)-Exenatide 2022972-68-3 98%
    (β-Asp28)-Exenatide is a potential degradation product of exenatide produced by the formation and cleavage of asparagine.
    (β-Asp28)-Exenatide
  • HY-P4745
    hMCH-1R antagonist 1 353487-64-6 98%
    hMCH-1R antagonist 1 (Compound 30) is an effective and selective antagonist of human melanin-concentrating hormone receptor 1 (hMCHR1) with an KB value of 3.6 nM. HMCH-1R antagonist 1 can bind to hMCHR1 and hMCHR2 with IC50 values of 65 nM and 49 nM, respectively. HMCH-1R antagonistist 1 can be used for metabolic research.
    hMCH-1R antagonist 1
  • HY-P4786
    Acetyl-ACTH (7-24) (human, bovine, rat) 1815618-01-9 98%
    Acetyl-ACTH (7-24) (human, bovine, rat) causes a marked decrease of ACTH-evoked corticosterone and aldosterone release.
    Acetyl-ACTH (7-24) (human, bovine, rat)
  • HY-P4790
    Acetyl-Exenatide 305815-28-5 98%
    Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation.
    Acetyl-Exenatide
  • HY-P4793
    Acetyl-Heme-Binding Protein 1 (1-21) (human) 946571-77-3 98%
    Acetyl-Heme-Binding Protein 1 (1-21) (human) is a short peptide. It consists of the first 21 amino acids of the hemopexin Acetyl-Heme-Binding Protein 1. Acetyl-Heme-Binding Protein 1 can bind to heme and play a role in heme metabolism and hemoglobin release.
    Acetyl-Heme-Binding Protein 1 (1-21) (human)
  • HY-P4800
    Osteostatin (human) 137348-10-8 98%
    Osteostatin (human), a fragment of parathyroid hormone-related protein (PTHrP) 107-139, promotes bone repair in animal models of bone defects and prevents bone erosion in inflammatory arthritis.
    Osteostatin (human)
  • HY-P4812
    Prepro-von Willebrand factor (641-650) (bovine) 143470-36-4 98%
    Prepro-von Willebrand factor (641-650) (bovine) is a fragment of Prepro-von Willebrand factor, which binds to type I collagen.
    Prepro-von Willebrand factor (641-650) (bovine)
  • HY-P4813
    Preptin (rat) 315197-73-0 98%
    Preptin, an osteogenic peptide product of the pancreatic beta-cell, corresponds to Asp69-Leu102 of pro-IGF-II.
    Preptin (rat)
  • HY-P4815
    Prokineticin 2 Isoform 2 (human) 423206-00-2 98%
    Prokineticin 2 Isoform 2 (human) is a hypothalamic neuropeptide. Prokineticin 2 Isoform 2 (human) decreases food intake and involves in thermoregulation and energy metabolism in rodents. Prokineticin 2 has the potential for the research of hyperglycemia, metabolic syndrome (MetS) and obesity.
    Prokineticin 2 Isoform 2 (human)
  • HY-P4817
    Human PTH-(1-31) 157938-23-3 98%
    Human PTH-(1-31) is the 1-31 fragment of human PTH. Human PTH-(1-31) stimulates the release of cAMP and also is a weaker stimulator of the 25-hydroxyvitamin D-1α-hydroxylase. Human PTH-(1-31) induces bone formation without inducing bone resorption. Human PTH-(1-31) has the potential for the research of osteoporosis.
    Human PTH-(1-31)
  • HY-P4818
    Human PTH-(1-31) amide 173833-08-4 98%
    Human PTH-(1-31) amide is a PTH analog. Human PTH-(1-31) amide stimulate phosphatidylcholine hydrolysis and stimulates adenylyl cyclase release.
    Human PTH-(1-31) amide
  • HY-P4827
    pTH (1-84) (dog) 521986-14-1 98%
    pTH (1-84) dog is a biologically active full-length canine parathyroid hormone, as well as an agonist of PTHR. pTH (1-84) dog can be detected by the "intact" PTH (W-PTH) assay, thus effectively distinguishing inactive C-terminal fragments. In terms of metabolic regulation, it rapidly and persistently stimulates hepatic glucose release, hepatic alanine uptake, and alanine-based gluconeogenesis in conscious fasted dogs, and causes a secondary increase in circulating canine insulin levels due to enhanced glucose release. However, high doses of pTH (1-84) (dog) may induce adverse reactions such as hypercalcemia in dogs. Based on the above characteristics, this hormone can be widely used in studies related to canine hyperadrenocorticism (HAC).
    pTH (1-84) (dog)
  • HY-P4839
    GLP-2 (1-34) (human) 99120-49-7 98%
    GLP-2 (1-34) (human) is a polypeptide released from the intestine within minutes after food intake. GLP-2 (1-34) (human) can be used for the research of bone remodeling processes.
    GLP-2 (1-34) (human)
Cat. No. Product Name / Synonyms Application Reactivity